{
    "info": {
        "nct_id": "NCT03087071",
        "official_title": "A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients",
        "inclusion_criteria": "* Histologically or cytologically confirmed colorectal adenocarcinoma, with metastatic disease documented on diagnostic imaging studies\n* Progression during or within 6 months after fluoropyrimidine, irinotecan, and oxaliplatin; for oxaliplatin-based therapy, failure of therapy will also include patients who progressed within 12 months of adjuvant therapy and patients who had oxaliplatin discontinued secondary to toxicity or allergic reaction; patients with a known history of Gilbert's disease who cannot receive irinotecan or patients who are intolerant of irinotecan or fluoropyrimidine are eligible\n* Confirmed wild-type status in KRAS exons 2, 3, and 4; NRAS exons 2, 3, and 4; and BRAF, by standard of care testing of tumor specimen; tissue used for testing may have been collected prior to treatment with anti-EGFR therapy\n* Patient must have been already tested and have available results of the mutations status of KRAS/NRAS/BRAF/MEK (MAP2K1) and EGFR from the circulating tumor DNA within 10 weeks prior to starting study therapy\n* Previous treatment with anti-EGFR therapy with evidence of clinical benefit, as defined by complete response, partial response, or prolonged stable disease with 16 or more weeks of treatment without radiographic progression, as assessed by the treating physician and documented in the medical record; this treatment may have occurred at any point in the patient's clinical course for treatment of metastatic colorectal cancer\n* Ultimate progression through previous treatment with anti-EGFR therapy, with documented clinical progression; patients who discontinued anti-EGFR therapy for any other reason, such as decline in performance status, hypersensitivity, or other adverse effects of therapy, are not eligible\n* All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) =< grade 1 (except =< grade 2 for alopecia peripheral neuropathy)\n* Radiographically measurable disease present per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Blood counts performed within 3 weeks prior to starting study therapy must have absolute neutrophil count >= 1,500/mm^3\n* Blood counts performed within 3 weeks prior to starting study therapy must have platelets >= 100,000/mm^3\n* Blood counts performed within 3 weeks prior to starting study therapy must have hemoglobin >= 9 g/dL\n* Liver function tests performed within 3 weeks prior to starting study therapy must have total bilirubin =< 1.5 x upper limit of normal (ULN)\n* Liver function tests performed within 3 weeks prior to starting study therapy must have alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)\n* Liver function tests performed within 3 weeks prior to starting study therapy must have albumin >= 2.5 g/dL\n* Serum creatinine performed within 3 weeks prior to starting study therapy must be =< 1.5 x ULN, or have calculated creatinine clearance (using Cockcroft-Gault formula) of >= 50 mL/minute\n* Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) performed within 3 weeks prior to starting study therapy must be =< 1.5 x ULN\n* Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 3 weeks prior to starting study therapy\n* Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and must agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment\n* Ability to sign informed consent form; informed consent form for this study must be signed prior to the performance of any study-specific procedures and initiation of any study therapy\n* Ability to swallow and retain oral medication, with no clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels\n* In cohort 1, must have EGFR S492R or other ectodomain mutation detected from circulating tumor DNA from plasma collected after progression on prior anti-EGFR therapy; may have a concomitant mutation in KRAS, NRAS, or BRAF, if there is at least a 5-fold higher allele frequency of the most prevalent EGFR mutation than the most prevalent KRAS/NRAS/BRAF mutation\n* In cohort 2, must have one or more mutations found in KRAS exon 2, 3, or 4; NRAS exon 2, 3, or 4; BRAF codon 600; or in MEK (MAP2K1); may have a concomitant EGFR ectodomain mutation, if the most prevalent EGFR ectodomain mutation does not have over a 5-fold higher allele frequency than the most prevalent KRAS/NRAS/BRAF mutation\n* In cohort 3, must not have EGFR ectodomain mutation or any mutations in KRAS, NRAS, or BRAF\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Past treatment with any MEK or ERK inhibitor\n* Previous retreatment with anti-EGFR therapy following progression on initial course of anti-EGFR therapy\n* Known untreated brain metastasis or brain metastasis treated within 3 months prior to enrollment in this trial\n* Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression\n* History of interstitial lung disease or pneumonitis\n* History of any other malignancy within 3 years, except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer and/or subjects with indolent second malignancies are eligible\n* Prior treatment within 21 days of the first dose of study drug with any other chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment, or failure to recover from adverse effects of prior therapies administered over 4 weeks prior to study day 1; all toxicities from prior therapies must be =< grade 1 (or =< grade 2 for alopecia or peripheral neuropathy); prior systemic treatment in the adjuvant setting is allowed\n* Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to randomization and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to randomization\n* Impaired cardiac function or clinically significant cardiac disease, as defined: a) left ventricular ejection fraction < lower limit of normal (LLN) on multiple gated acquisition scan (MUGA) or echocardiogram; b) congenital long QT syndrome or family history of unexpected sudden cardiac death; c) corrected QT (QTc) corrected with Bazett's formula (QTcB) >= 480 ms.; d) history or evidence of current clinically significant uncontrolled arrhythmias; note subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible; e) history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization; f) history or evidence of current >= class II congestive heart failure as defined by New York Heart Association (NYHA); g) treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy; h) patients with intra-cardiac defibrillators\n* Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent, or compliance to the study procedures\n* History of retinal vein occlusion (RVO)\n* Pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment\n* History of organ allograft or other history of immunodeficiency\n* Inability or unwillingness to comply with study and/or follow-up requirements\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)\n* Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; subjects with laboratory evidence of cleared HBV and HCV infection will be permitted\n* Current use of a prohibited medication",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Previous treatment with anti-EGFR therapy with evidence of clinical benefit, as defined by complete response, partial response, or prolonged stable disease with 16 or more weeks of treatment without radiographic progression, as assessed by the treating physician and documented in the medical record; this treatment may have occurred at any point in the patient's clinical course for treatment of metastatic colorectal cancer",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with anti-EGFR therapy",
                    "criterion": "anti-EGFR therapy",
                    "requirements": [
                        {
                            "requirement_type": "previous treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of clinical benefit, as defined by complete response, partial response, or prolonged stable disease with 16 or more weeks of treatment without radiographic progression",
                    "criterion": "clinical benefit from anti-EGFR therapy",
                    "requirements": [
                        {
                            "requirement_type": "response type",
                            "expected_value": [
                                "complete response",
                                "partial response"
                            ]
                        },
                        {
                            "requirement_type": "stable disease duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 16,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "radiographic progression",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed by the treating physician and documented in the medical record",
                    "criterion": "clinical benefit assessment documentation",
                    "requirements": [
                        {
                            "requirement_type": "assessment by treating physician",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation in medical record",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "this treatment may have occurred at any point in the patient's clinical course for treatment of metastatic colorectal cancer",
                    "criterion": "timing of anti-EGFR therapy for metastatic colorectal cancer",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "any point in clinical course for metastatic colorectal cancer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient must have been already tested and have available results of the mutations status of KRAS/NRAS/BRAF/MEK (MAP2K1) and EGFR from the circulating tumor DNA within 10 weeks prior to starting study therapy",
            "criterions": [
                {
                    "exact_snippets": "already tested and have available results of the mutations status of KRAS/NRAS/BRAF/MEK (MAP2K1) and EGFR from the circulating tumor DNA",
                    "criterion": "mutation status of KRAS/NRAS/BRAF/MEK (MAP2K1) and EGFR from circulating tumor DNA",
                    "requirements": [
                        {
                            "requirement_type": "testing_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "results_availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 10 weeks prior to starting study therapy",
                    "criterion": "timing of mutation status testing",
                    "requirements": [
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "weeks prior to starting study therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) =< grade 1 (except =< grade 2 for alopecia peripheral neuropathy)",
            "criterions": [
                {
                    "exact_snippets": "All prior treatment-related toxicities ... must be ... =< grade 1",
                    "criterion": "prior treatment-related toxicities",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(except =< grade 2 for alopecia peripheral neuropathy)",
                    "criterion": "alopecia peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiographically measurable disease present per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
            "criterions": [
                {
                    "exact_snippets": "Radiographically measurable disease present per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
                    "criterion": "measurable disease (per RECIST 1.1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurability (per RECIST 1.1)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed wild-type status in KRAS exons 2, 3, and 4; NRAS exons 2, 3, and 4; and BRAF, by standard of care testing of tumor specimen; tissue used for testing may have been collected prior to treatment with anti-EGFR therapy",
            "criterions": [
                {
                    "exact_snippets": "Confirmed wild-type status in KRAS exons 2, 3, and 4",
                    "criterion": "KRAS gene (exons 2, 3, and 4)",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wild-type"
                        }
                    ]
                },
                {
                    "exact_snippets": "Confirmed wild-type status in ... NRAS exons 2, 3, and 4",
                    "criterion": "NRAS gene (exons 2, 3, and 4)",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wild-type"
                        }
                    ]
                },
                {
                    "exact_snippets": "Confirmed wild-type status in ... BRAF",
                    "criterion": "BRAF gene",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wild-type"
                        }
                    ]
                },
                {
                    "exact_snippets": "by standard of care testing of tumor specimen",
                    "criterion": "tumor specimen testing method",
                    "requirements": [
                        {
                            "requirement_type": "testing method",
                            "expected_value": "standard of care"
                        }
                    ]
                },
                {
                    "exact_snippets": "tissue used for testing may have been collected prior to treatment with anti-EGFR therapy",
                    "criterion": "timing of tissue collection relative to anti-EGFR therapy",
                    "requirements": [
                        {
                            "requirement_type": "collection timing",
                            "expected_value": "prior to anti-EGFR therapy (allowed)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progression during or within 6 months after fluoropyrimidine, irinotecan, and oxaliplatin; for oxaliplatin-based therapy, failure of therapy will also include patients who progressed within 12 months of adjuvant therapy and patients who had oxaliplatin discontinued secondary to toxicity or allergic reaction; patients with a known history of Gilbert's disease who cannot receive irinotecan or patients who are intolerant of irinotecan or fluoropyrimidine are eligible",
            "criterions": [
                {
                    "exact_snippets": "Progression during or within 6 months after fluoropyrimidine, irinotecan, and oxaliplatin",
                    "criterion": "disease progression after chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "progression_timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for oxaliplatin-based therapy, failure of therapy will also include patients who progressed within 12 months of adjuvant therapy",
                    "criterion": "disease progression after adjuvant oxaliplatin-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression_timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who had oxaliplatin discontinued secondary to toxicity or allergic reaction",
                    "criterion": "oxaliplatin discontinuation due to toxicity or allergic reaction",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_reason",
                            "expected_value": [
                                "toxicity",
                                "allergic reaction"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with a known history of Gilbert's disease who cannot receive irinotecan or patients who are intolerant of irinotecan or fluoropyrimidine are eligible",
                    "criterion": "inability to receive irinotecan or fluoropyrimidine",
                    "requirements": [
                        {
                            "requirement_type": "inability_reason",
                            "expected_value": [
                                "Gilbert's disease",
                                "intolerance"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with a known history of Gilbert's disease",
                    "criterion": "history of Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed colorectal adenocarcinoma, with metastatic disease documented on diagnostic imaging studies",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed colorectal adenocarcinoma",
                    "criterion": "colorectal adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic disease documented on diagnostic imaging studies",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "documentation method",
                            "expected_value": "diagnostic imaging studies"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Blood counts performed within 3 weeks prior to starting study therapy must have absolute neutrophil count >= 1,500/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Blood counts performed within 3 weeks prior to starting study therapy",
                    "criterion": "blood counts",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 3 weeks prior to starting study therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "absolute neutrophil count >= 1,500/mm^3",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ultimate progression through previous treatment with anti-EGFR therapy, with documented clinical progression; patients who discontinued anti-EGFR therapy for any other reason, such as decline in performance status, hypersensitivity, or other adverse effects of therapy, are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Ultimate progression through previous treatment with anti-EGFR therapy, with documented clinical progression",
                    "criterion": "progression on anti-EGFR therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": "clinical progression"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who discontinued anti-EGFR therapy for any other reason, such as decline in performance status, hypersensitivity, or other adverse effects of therapy, are not eligible",
                    "criterion": "discontinuation of anti-EGFR therapy for reasons other than progression",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation reason",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "progression"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Blood counts performed within 3 weeks prior to starting study therapy must have hemoglobin >= 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Blood counts performed within 3 weeks prior to starting study therapy",
                    "criterion": "blood counts",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 3 weeks prior to starting study therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin >= 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Blood counts performed within 3 weeks prior to starting study therapy must have platelets >= 100,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Blood counts performed within 3 weeks prior to starting study therapy",
                    "criterion": "blood counts",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 3 weeks prior to starting study therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "platelets >= 100,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Liver function tests performed within 3 weeks prior to starting study therapy must have total bilirubin =< 1.5 x upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Liver function tests performed within 3 weeks prior to starting study therapy",
                    "criterion": "liver function tests",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 3 weeks prior to starting study therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Liver function tests performed within 3 weeks prior to starting study therapy must have alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)",
            "criterions": [
                {
                    "exact_snippets": "Liver function tests performed within 3 weeks prior to starting study therapy",
                    "criterion": "liver function tests",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 3 weeks prior to starting study therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase ... =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)",
                    "criterion": "alanine aminotransferase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if liver metastases are present)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase ... =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)",
                    "criterion": "aspartate aminotransferase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (if liver metastases are present)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Liver function tests performed within 3 weeks prior to starting study therapy must have albumin >= 2.5 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Liver function tests performed within 3 weeks prior to starting study therapy",
                    "criterion": "liver function tests",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 3 weeks prior to starting study therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "albumin >= 2.5 g/dL",
                    "criterion": "albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine performed within 3 weeks prior to starting study therapy must be =< 1.5 x ULN, or have calculated creatinine clearance (using Cockcroft-Gault formula) of >= 50 mL/minute",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ... must be =< 1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance (using Cockcroft-Gault formula) of >= 50 mL/minute",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/minute"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) performed within 3 weeks prior to starting study therapy must be =< 1.5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Prothrombin time (PT)/international normalized ratio (INR) ... must be =< 1.5 x ULN",
                    "criterion": "prothrombin time (PT)/international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "partial thromboplastin time (PTT) ... must be =< 1.5 x ULN",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "performed within 3 weeks prior to starting study therapy",
                    "criterion": "timing of PT/INR and PTT tests",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 3 weeks prior to starting study therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 3 weeks prior to starting study therapy",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN)",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "LLN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)",
                    "criterion": "LVEF measurement method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "echocardiogram (ECHO)",
                                "multiple gated acquisition scan (MUGA)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "within 3 weeks prior to starting study therapy",
                    "criterion": "LVEF assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks prior to starting study therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to sign informed consent form; informed consent form for this study must be signed prior to the performance of any study-specific procedures and initiation of any study therapy",
            "criterions": [
                {
                    "exact_snippets": "Ability to sign informed consent form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "ability to sign",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "informed consent form for this study must be signed prior to the performance of any study-specific procedures and initiation of any study therapy",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed before study procedures or therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization and must agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum pregnancy test within 14 days prior to randomization",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "throughout the treatment period",
                                "for 4 months after the last dose of study treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to swallow and retain oral medication, with no clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels",
            "criterions": [
                {
                    "exact_snippets": "Ability to swallow and retain oral medication",
                    "criterion": "ability to swallow and retain oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no clinically significant gastrointestinal abnormalities that may alter absorption",
                    "criterion": "gastrointestinal abnormalities that may alter absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "such as malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "major resection of the stomach or bowels",
                    "criterion": "major resection of the stomach or bowels",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In cohort 1, must have EGFR S492R or other ectodomain mutation detected from circulating tumor DNA from plasma collected after progression on prior anti-EGFR therapy; may have a concomitant mutation in KRAS, NRAS, or BRAF, if there is at least a 5-fold higher allele frequency of the most prevalent EGFR mutation than the most prevalent KRAS/NRAS/BRAF mutation",
            "criterions": [
                {
                    "exact_snippets": "must have EGFR S492R or other ectodomain mutation detected from circulating tumor DNA from plasma collected after progression on prior anti-EGFR therapy",
                    "criterion": "EGFR mutation (S492R or other ectodomain)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "circulating tumor DNA from plasma"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after progression on prior anti-EGFR therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "may have a concomitant mutation in KRAS, NRAS, or BRAF, if there is at least a 5-fold higher allele frequency of the most prevalent EGFR mutation than the most prevalent KRAS/NRAS/BRAF mutation",
                    "criterion": "concomitant mutation in KRAS, NRAS, or BRAF",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "allele frequency ratio",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "fold higher (EGFR vs KRAS/NRAS/BRAF)"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In cohort 3, must not have EGFR ectodomain mutation or any mutations in KRAS, NRAS, or BRAF",
            "criterions": [
                {
                    "exact_snippets": "must not have EGFR ectodomain mutation",
                    "criterion": "EGFR ectodomain mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have ... any mutations in KRAS, NRAS, or BRAF",
                    "criterion": "KRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have ... any mutations in KRAS, NRAS, or BRAF",
                    "criterion": "NRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have ... any mutations in KRAS, NRAS, or BRAF",
                    "criterion": "BRAF mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* In cohort 2, must have one or more mutations found in KRAS exon 2, 3, or 4; NRAS exon 2, 3, or 4; BRAF codon 600; or in MEK (MAP2K1); may have a concomitant EGFR ectodomain mutation, if the most prevalent EGFR ectodomain mutation does not have over a 5-fold higher allele frequency than the most prevalent KRAS/NRAS/BRAF mutation",
            "criterions": [
                {
                    "exact_snippets": "must have one or more mutations found in KRAS exon 2, 3, or 4",
                    "criterion": "KRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "exon 2",
                                "exon 3",
                                "exon 4"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have one or more mutations found in ... NRAS exon 2, 3, or 4",
                    "criterion": "NRAS mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "exon 2",
                                "exon 3",
                                "exon 4"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have one or more mutations found in ... BRAF codon 600",
                    "criterion": "BRAF mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "codon 600"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have one or more mutations found in ... MEK (MAP2K1)",
                    "criterion": "MEK (MAP2K1) mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "may have a concomitant EGFR ectodomain mutation, if the most prevalent EGFR ectodomain mutation does not have over a 5-fold higher allele frequency than the most prevalent KRAS/NRAS/BRAF mutation",
                    "criterion": "EGFR ectodomain mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "may have"
                        },
                        {
                            "requirement_type": "allele frequency comparison",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "fold higher than the most prevalent KRAS/NRAS/BRAF mutation"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Current use of a prohibited medication",
            "criterions": [
                {
                    "exact_snippets": "Current use of a prohibited medication",
                    "criterion": "prohibited medication use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent, or compliance to the study procedures",
            "criterions": [
                {
                    "exact_snippets": "Any serious and/or unstable pre-existing medical disorder (aside from malignancy exception above)",
                    "criterion": "pre-existing medical disorder",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "serious and/or unstable"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric disorder",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other conditions that could interfere with subject's safety, obtaining informed consent, or compliance to the study procedures",
                    "criterion": "other conditions interfering with safety, consent, or compliance",
                    "requirements": [
                        {
                            "requirement_type": "interference with safety, consent, or compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of interstitial lung disease or pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "History of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Past treatment with any MEK or ERK inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Past treatment with any MEK or ERK inhibitor",
                    "criterion": "past treatment with MEK or ERK inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability or unwillingness to comply with study and/or follow-up requirements",
            "criterions": [
                {
                    "exact_snippets": "Inability or unwillingness to comply with study and/or follow-up requirements",
                    "criterion": "compliance with study and/or follow-up requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability and willingness to comply",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of organ allograft or other history of immunodeficiency",
            "criterions": [
                {
                    "exact_snippets": "History of organ allograft",
                    "criterion": "organ allograft",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other history of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known untreated brain metastasis or brain metastasis treated within 3 months prior to enrollment in this trial",
            "criterions": [
                {
                    "exact_snippets": "Known untreated brain metastasis",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "knowledge",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "brain metastasis treated within 3 months prior to enrollment in this trial",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "treatment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous retreatment with anti-EGFR therapy following progression on initial course of anti-EGFR therapy",
            "criterions": [
                {
                    "exact_snippets": "Previous retreatment with anti-EGFR therapy",
                    "criterion": "retreatment with anti-EGFR therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "following progression on initial course of anti-EGFR therapy",
                    "criterion": "progression on initial course of anti-EGFR therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of retinal vein occlusion (RVO)",
            "criterions": [
                {
                    "exact_snippets": "History of retinal vein occlusion (RVO)",
                    "criterion": "retinal vein occlusion (RVO)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "planning to become pregnant within 6 months after the end of treatment",
                    "criterion": "pregnancy intention within 6 months after treatment",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of any other malignancy within 3 years, except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer and/or subjects with indolent second malignancies are eligible",
            "criterions": [
                {
                    "exact_snippets": "History of any other malignancy within 3 years",
                    "criterion": "history of other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer",
                    "criterion": "history of carcinoma in situ of the cervix or non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with indolent second malignancies are eligible",
                    "criterion": "indolent second malignancies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection; subjects with laboratory evidence of cleared HBV and HCV infection will be permitted",
            "criterions": [
                {
                    "exact_snippets": "Known human immunodeficiency virus (HIV) ... infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B virus (HBV) ... infection",
                    "criterion": "HBV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "cleared infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C virus (HCV) ... infection",
                    "criterion": "HCV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "cleared infection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic ... leptomeningeal ... metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated leptomeningeal ... metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Symptomatic ... brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated ... brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "spinal cord compression",
                    "criterion": "spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to randomization and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Any major surgery ... within 21 days prior to randomization",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "extensive radiotherapy ... within 21 days prior to randomization",
                    "criterion": "extensive radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy with delayed toxicity ... within 21 days prior to randomization",
                    "criterion": "chemotherapy with delayed toxicity",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "biologic therapy ... within 21 days prior to randomization",
                    "criterion": "biologic therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immunotherapy within 21 days prior to randomization",
                    "criterion": "immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to randomization",
                    "criterion": "daily or weekly chemotherapy without the potential for delayed toxicity",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Impaired cardiac function or clinically significant cardiac disease, as defined: a) left ventricular ejection fraction < lower limit of normal (LLN) on multiple gated acquisition scan (MUGA) or echocardiogram; b) congenital long QT syndrome or family history of unexpected sudden cardiac death; c) corrected QT (QTc) corrected with Bazett's formula (QTcB) >= 480 ms.; d) history or evidence of current clinically significant uncontrolled arrhythmias; note subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible; e) history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization; f) history or evidence of current >= class II congestive heart failure as defined by New York Heart Association (NYHA); g) treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy; h) patients with intra-cardiac defibrillators",
            "criterions": [
                {
                    "exact_snippets": "left ventricular ejection fraction < lower limit of normal (LLN) on multiple gated acquisition scan (MUGA) or echocardiogram",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 0,
                                "unit": "LLN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "congenital long QT syndrome or family history of unexpected sudden cardiac death",
                    "criterion": "congenital long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of unexpected sudden cardiac death",
                    "criterion": "family history of unexpected sudden cardiac death",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "corrected QT (QTc) corrected with Bazett's formula (QTcB) >= 480 ms.",
                    "criterion": "corrected QT interval (QTcB)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 480,
                                "unit": "ms"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history or evidence of current clinically significant uncontrolled arrhythmias; note subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible",
                    "criterion": "clinically significant uncontrolled arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization",
                    "criterion": "acute coronary syndromes, coronary angioplasty, or stenting within 6 months",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": "within 6 months prior to randomization"
                        }
                    ]
                },
                {
                    "exact_snippets": "history or evidence of current >= class II congestive heart failure as defined by New York Heart Association (NYHA)",
                    "criterion": "congestive heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy",
                    "criterion": "treatment refractory hypertension",
                    "requirements": [
                        {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 140,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "control_by_anti-hypertensive_therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with intra-cardiac defibrillators",
                    "criterion": "intra-cardiac defibrillator",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment within 21 days of the first dose of study drug with any other chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment, or failure to recover from adverse effects of prior therapies administered over 4 weeks prior to study day 1; all toxicities from prior therapies must be =< grade 1 (or =< grade 2 for alopecia or peripheral neuropathy); prior systemic treatment in the adjuvant setting is allowed",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment within 21 days of the first dose of study drug with any other chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment",
                    "criterion": "prior treatment with chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "failure to recover from adverse effects of prior therapies administered over 4 weeks prior to study day 1",
                    "criterion": "recovery from adverse effects of prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "recovery",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since prior therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "all toxicities from prior therapies must be =< grade 1 (or =< grade 2 for alopecia or peripheral neuropathy)",
                    "criterion": "toxicities from prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "toxicity grade (general)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "toxicity grade (alopecia or peripheral neuropathy)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO)",
            "criterions": [
                {
                    "exact_snippets": "Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug",
                    "criterion": "hypersensitivity or idiosyncrasy to drugs chemically related to study drug",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity reaction or idiosyncrasy ... to excipients",
                    "criterion": "hypersensitivity or idiosyncrasy to excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity reaction or idiosyncrasy ... to dimethyl sulfoxide (DMSO)",
                    "criterion": "hypersensitivity or idiosyncrasy to dimethyl sulfoxide (DMSO)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}